Rafferty Asset Management
ZVRA icon

Rafferty Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Rafferty Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
+11,224
New +$125K ﹤0.01% 1120
2026
Q1 		– Sell
-15,920
Closed -$143K – 1148
2025
Q4 		$143K Buy
15,920
+4,041
+34% +$38.2K ﹤0.01% 1118
2025
Q3 		$113K Buy
+11,879
New +$119K ﹤0.01% 1096

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rafferty Asset Management's ZVRA Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 11,224 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #1120 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in ZVRA as recently as Q4 2025.

Rafferty Asset Management first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Rafferty Asset Management held 11,224 shares of Zevra Therapeutics worth $161K as of Q2 2026.
  • Zevra Therapeutics was a new Rafferty Asset Management position in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1120 holding.
  • Rafferty Asset Management first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.